Penumbra’s SwiftPAC Neuroembolization Coil Receives CE Mark Approval

September 15, 2025—Penumbra Inc. announced it has secured CE Mark approval for its SwiftPAC neuroembolization coil. The device, which is now commercially available in Europe, is part of the company’s Swift coil system.

According to Penumbra, SwiftPAC has a 0.0135-inch primary diameter deliverable through 0.0165-inch microcatheters and is available in a range of lengths from 3 to 60 cm to optimize embolization across vessel sizes and anatomy. The coils are designed as a soft space-seeking “liquid metal” that conforms to the target vessel for dense packing. This provides versatility across a variety of clinical applications.

Additionally, the SwiftPAC device is a 10-system coil that has a softness value of 0.093. It features a two-dimensional sinusoidal shape to help the coil break effortlessly to seek empty space and allows physicians to deploy and reposition with precision before detaching, noted Penumbra.

“The shapeless design of the new SwiftPAC coil allows for efficient, dense occlusion of the middle meningeal artery branches in awake patients and the essential control to avoid dangerous anastomoses,” said Johannes Hensler, MD, in Penumbra’s press release. Dr. Hensler is a senior physician at the University Hospital Schleswig-Holstein in Kiel, Germany.